The special immunotherapy edition of Perspective magazine is live
| 19th May 2016
As a creative marketing consultancy, we have a unique perspective on the challenges facing the broad range of stakeholders in the healthcare and pharma industry. As such, we've created this magazine to explore those challenges in depth from a variety of viewpoints.
In this supplementary issue, we’re taking a special look at immunotherapies, and more specifically, the growing buzz around “immuno-oncology” therapies. At the time of publication, Blue Latitude Health have worked with four of the eight immunotherapies currently approved by the FDA, so we’ve pooled our expertise across the different capabilities to give you a clear view on the fourth pillar of care in oncology.
The immunotherapy special issue covers:
- Immunology in oncology as a therapy area – what it is, how it works, and where it’s heading from a medical and commercial point of view.
- Key insights around positioning immuno-oncology products based on our hands-on experience working in this area.
- What new immunotherapies in oncology mean for cancer patients and the doctors who would prescribe them, and in turn, what that means for pharma.
- The immuno-therapy patient experience as a customer journey.
Click the button below to enter your details and receive your digital copy.
Achieving deep understanding of healthcare customer behaviour
| 18th October 2017
In part one of a series on customer insight and behaviour change, Martine Leroy reveals a behaviour framework for gathering sharp insights used to help brand managers and marketers achieve their business goals and create a customer-centric strategy.
How do you define a biotech company?
| 6th October 2017
We ask if the defnition of biotech needs updating as big pharma turns its research and development aims to biological therapies.
Emerging technologies in biotech
| 25th September 2017
Associate Consultant Ditte Funding and Content Marketing Executive Natasha Cowan explore the transformative technologies revolutionising the biotech industry, from CAR-T to CRISPR.